Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486489 | 0.80 | NPC1 (0.46) | HDAC1HDAC8HDAC6HPGDRAB9A | |
| SCHEMBL4487564 | 0.80 | CNR1 (0.39) | HDAC1HDAC8HDAC6HPGDRAB9A | |
| SCHEMBL749646 | 0.78 | HDAC1 (0.42) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL158296 | 0.78 | HDAC1 (0.39) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL749645 | 0.77 | HDAC1 (0.38) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL21423708 | 0.77 | FBP1 (0.49) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL18236189 | 0.77 | HDAC1 (0.45) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL4484701 | 0.77 | DAGLA (0.42) | HDAC1HDAC8HDAC6RAB9ANPC1 | |
| SCHEMBL25153630 | 0.74 | HDAC6 (0.40) | HDAC1HDAC8HDAC6BAZ2BHPGD | |
| SCHEMBL26795642 | 0.74 | IRAK4 (0.40) | HDAC1HDAC8HDAC6BAZ2BHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | HDAC1 691/4885HDAC8 2377/4885HDAC6 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.